Loading...
Publication
Effectiveness of long-acting monoclonal antibodies against laboratory-confirmed RSV in children aged < 24 months and hospitalised for severe acute respiratory infection, European pilot study, 2024 to 2025
| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 332.57 KB | Adobe PDF |
Advisor(s)
Abstract(s)
We measured effectiveness of nirsevimab against laboratory-confirmed respiratory syncytial virus (RSV) infection in a test-negative case-control study among children aged < 24 months hospitalised for severe acute respiratory infection in three European countries. The overall effectiveness in the 2024/25 season among 2,201 children was 79% (95% CI: 58 to 89) and 85%, 78% and 69% at < 30, 30-89 and 90-215 days since immunisation. Immunisation was effective for preventing RSV-related hospitalisation in children, but effectiveness by time since immunisation needs monitoring in future seasons.
Description
VEBIS hospital network RSV IE group: Eva Bernaert, Reinout Naesens, Bénédicte Lissoir, Catherine Sion, Sandra Koenig, Xavier Holemans, Bénédicte Delaere, David Tuerlinckx, Marc Bourgeois, Marijke Reynders, Vanessa Verbeke, Catherine Quoidbach, Francesco Genderini, Gabriella Kollar, Nicolas Dauby, Arthur Eggerickx, Arne Witdouck, Deborah De Geyter, Eveline Van Honacker, Lucie Seyler, Siel Daelemans, Koen Magerman, Marlies Blommen, Natasja Detillieu, Veerle Penders, Melanie Delvallee, Pierre Struyven, Isabel Leroux-Roels, Pascal De Waegemaeker, Silke Ternest, Anna Parys, François Dufrasne, Sarah Denayer, Claire Brugerolles, Laurane De Mot, Peace Mpakaniye, Sébastien Fierens, Sven Hanoteaux, Yinthe Dockx, Yves Lafort, Nathalie Bossuyt, Marcos Lozano Alvarez, María Iglesias-Caballero, Gloria Pérez Gimeno, Noa Batalla Rebollo, Irene Pedrosa Corral, Manuel García Cenoz, Guillermo Ezpeleta, Nerea Egüés, Noelia Vera-Punzano, Ana Navascués, Leticia Armendáriz, Ausenda Machado, Miguel Lança, Camila Henriques, Licínia Gomes, Diogo Marques, Madelyn Rojas, Anthony Nardone.
Keywords
RSV Monoclonal Antibodies Nirsevimab Effectiveness Europe Determinantes da Saúde e da Doença Observação em Saúde e Vigilância Infecções Respiratórias
Pedagogical Context
Citation
Euro Surveill. 2025 Nov;30(45):2500816. doi: 10.2807/1560-7917.ES.2025.30.45.2500816
Publisher
European Centre for Disease Prevention and Control